{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 28,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses two waterfall/spider plots to demonstrate efficacy in different clinical settings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/14",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.42,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Sotigalimab clinical data demonstrate durable single-agent anti-tumor activity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53b7ee1c-6d1a-4a05-8b05-eba7c76e56b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.48,
        "x": 0.48,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Single-arm trial with 15% confirmed response and durability is likely sufficient for BLA approval",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "969fce95-6847-46df-8379-a7add0f23f9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.42,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "chart",
      "text": "SINGLE-AGENT ANTI-TUMOR ACTIVITY",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e2afda8-9a95-4843-a596-8f1cdba77145",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.48,
        "x": 0.48,
        "y": 0.23
      },
      "kind": "chart",
      "text": "EXTENDED DURATION OF RESPONSE IN COMBINATION WITH ANTI-PD-1",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce5d5e63-efa3-4461-851c-4a682cf9a018",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "source-note",
      "text": "Data snapshot from Dec 2021. Investigator-assessment by RECIST 1.1.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0087785-8182-4f1d-b2da-b648ef5a13e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Anti-tumor Effects of Sotigalimab in Melanoma: Single-Agent and anti-PD-1 Combination Efficacy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22d7720f-b88b-4991-8811-1dd8656001b6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 10,
      "beatId": "eabcce46-c7fe-4e05-b519-ae0aa88c80cb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The deck provides details on Sotigalimab's clinical development program and potential applications.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}